Clinical and economic assessment of the therapy of acute kidney injury in sepsis with continuous combined methods of renal replacement therapy
Objective: complex assessment of clinical and economic effectiveness as well as saving of the state budget assets within the therapy of patients with sepsis/septic shock based on different technologies of blood purification.Methods. Evaluation of direct and indirect costs of the eight blood purifcatio...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2021-11-01
|
| Series: | Вестник анестезиологии и реаниматологии |
| Subjects: | |
| Online Access: | https://www.vair-journal.com/jour/article/view/574 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849698358477717504 |
|---|---|
| author | Y. . S Polushin R. O. Dreval A. N. Zabotina |
| author_facet | Y. . S Polushin R. O. Dreval A. N. Zabotina |
| author_sort | Y. . S Polushin |
| collection | DOAJ |
| description | Objective: complex assessment of clinical and economic effectiveness as well as saving of the state budget assets within the therapy of patients with sepsis/septic shock based on different technologies of blood purification.Methods. Evaluation of direct and indirect costs of the eight blood purifcation methods. The target population includes adult patients 18+ with septic acute kidney injury. The study was conducted in compliance with acting Standards on Clinical Economic Studies used in the Russian Federation.The study methods included evaluation of existing randomized clinical studies and trials with data from network meta-analyses and systematic reviews of the target technologies. The direct medical and indirect non-medical costs were calculated and analyzed in respect of cost-effectiveness and budget impact analyses.Results. Direct and indirect costs were calculated for the sorption devices oXiris (Baxter International Inc.), Toraymyxin (Toray Medical Co.), Alteco LPS Adsorber (Alteco Medical AB), Toxipak (POKARD NPF), Desepta.LPS (BIOTECH M NPP), CytoSorb (CytoSorbents Inc.), HA330 (Jafron Biomedical Co.), Desepta (BIOTECH M NPP) for two time-horizons: 1-year period and 5-years period with discounting. For both periods, the use of oXiris hemoflter results in the least economic burden for the state budget.Conclusion. The use of blood purifcation in septic patients therapy is associated with considerable direct and indirect fnancial expenses, the amount of which and consequential budget saving depend on the technology of blood purifcation applied. The actual tariff compensation policy evidently demands revising. |
| format | Article |
| id | doaj-art-e8411bc21a484ee2874c2a7d2d42a5e1 |
| institution | DOAJ |
| issn | 2078-5658 2541-8653 |
| language | Russian |
| publishDate | 2021-11-01 |
| publisher | New Terra Publishing House |
| record_format | Article |
| series | Вестник анестезиологии и реаниматологии |
| spelling | doaj-art-e8411bc21a484ee2874c2a7d2d42a5e12025-08-20T03:18:55ZrusNew Terra Publishing HouseВестник анестезиологии и реаниматологии2078-56582541-86532021-11-0118572010.21292/2078-5658-2021-18-5-7-20466Clinical and economic assessment of the therapy of acute kidney injury in sepsis with continuous combined methods of renal replacement therapyY. . S Polushin0R. O. Dreval1A. N. Zabotina2Pavlov First Saint Petersburg State Medical UniversityNonproft Partnership Center for Social EconomicsNonproft Partnership Center for Social EconomicsObjective: complex assessment of clinical and economic effectiveness as well as saving of the state budget assets within the therapy of patients with sepsis/septic shock based on different technologies of blood purification.Methods. Evaluation of direct and indirect costs of the eight blood purifcation methods. The target population includes adult patients 18+ with septic acute kidney injury. The study was conducted in compliance with acting Standards on Clinical Economic Studies used in the Russian Federation.The study methods included evaluation of existing randomized clinical studies and trials with data from network meta-analyses and systematic reviews of the target technologies. The direct medical and indirect non-medical costs were calculated and analyzed in respect of cost-effectiveness and budget impact analyses.Results. Direct and indirect costs were calculated for the sorption devices oXiris (Baxter International Inc.), Toraymyxin (Toray Medical Co.), Alteco LPS Adsorber (Alteco Medical AB), Toxipak (POKARD NPF), Desepta.LPS (BIOTECH M NPP), CytoSorb (CytoSorbents Inc.), HA330 (Jafron Biomedical Co.), Desepta (BIOTECH M NPP) for two time-horizons: 1-year period and 5-years period with discounting. For both periods, the use of oXiris hemoflter results in the least economic burden for the state budget.Conclusion. The use of blood purifcation in septic patients therapy is associated with considerable direct and indirect fnancial expenses, the amount of which and consequential budget saving depend on the technology of blood purifcation applied. The actual tariff compensation policy evidently demands revising.https://www.vair-journal.com/jour/article/view/574sepsisseptic shockmultiple organ dysfunction syndromeacute kidney injuryblood purifcationpharmacoeconomicsclinical economic studycost effectivenessreplacement renal therapy |
| spellingShingle | Y. . S Polushin R. O. Dreval A. N. Zabotina Clinical and economic assessment of the therapy of acute kidney injury in sepsis with continuous combined methods of renal replacement therapy Вестник анестезиологии и реаниматологии sepsis septic shock multiple organ dysfunction syndrome acute kidney injury blood purifcation pharmacoeconomics clinical economic study cost effectiveness replacement renal therapy |
| title | Clinical and economic assessment of the therapy of acute kidney injury in sepsis with continuous combined methods of renal replacement therapy |
| title_full | Clinical and economic assessment of the therapy of acute kidney injury in sepsis with continuous combined methods of renal replacement therapy |
| title_fullStr | Clinical and economic assessment of the therapy of acute kidney injury in sepsis with continuous combined methods of renal replacement therapy |
| title_full_unstemmed | Clinical and economic assessment of the therapy of acute kidney injury in sepsis with continuous combined methods of renal replacement therapy |
| title_short | Clinical and economic assessment of the therapy of acute kidney injury in sepsis with continuous combined methods of renal replacement therapy |
| title_sort | clinical and economic assessment of the therapy of acute kidney injury in sepsis with continuous combined methods of renal replacement therapy |
| topic | sepsis septic shock multiple organ dysfunction syndrome acute kidney injury blood purifcation pharmacoeconomics clinical economic study cost effectiveness replacement renal therapy |
| url | https://www.vair-journal.com/jour/article/view/574 |
| work_keys_str_mv | AT yspolushin clinicalandeconomicassessmentofthetherapyofacutekidneyinjuryinsepsiswithcontinuouscombinedmethodsofrenalreplacementtherapy AT rodreval clinicalandeconomicassessmentofthetherapyofacutekidneyinjuryinsepsiswithcontinuouscombinedmethodsofrenalreplacementtherapy AT anzabotina clinicalandeconomicassessmentofthetherapyofacutekidneyinjuryinsepsiswithcontinuouscombinedmethodsofrenalreplacementtherapy |